EP3059307B2 - Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells - Google Patents

Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells Download PDF

Info

Publication number
EP3059307B2
EP3059307B2 EP15305265.9A EP15305265A EP3059307B2 EP 3059307 B2 EP3059307 B2 EP 3059307B2 EP 15305265 A EP15305265 A EP 15305265A EP 3059307 B2 EP3059307 B2 EP 3059307B2
Authority
EP
European Patent Office
Prior art keywords
cells
human
laminin
population
hepatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15305265.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3059307A1 (en
EP3059307B1 (en
Inventor
Tuan Huy NGUYEN
Angélique Fourrier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Nantes Université
Original Assignee
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52598699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3059307(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to HUE15305265A priority Critical patent/HUE041518T2/hu
Priority to RS20181530A priority patent/RS58070B2/sr
Priority to DK15305265.9T priority patent/DK3059307T5/da
Priority to HRP20182119TT priority patent/HRP20182119T4/hr
Priority to LTEP15305265.9T priority patent/LT3059307T/lt
Application filed by Universite de Nantes, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Universite de Nantes
Priority to SM20190005T priority patent/SMT201900005T1/it
Priority to SI201530533T priority patent/SI3059307T2/sl
Priority to ES15305265T priority patent/ES2703167T5/es
Priority to EP15305265.9A priority patent/EP3059307B2/en
Priority to PL15305265.9T priority patent/PL3059307T5/pl
Priority to PT15305265T priority patent/PT3059307T/pt
Priority to DK16705202.6T priority patent/DK3259345T5/da
Priority to US15/551,551 priority patent/US20180030415A1/en
Priority to CN202010391416.6A priority patent/CN111548985A/zh
Priority to SI201631673T priority patent/SI3259345T1/sl
Priority to FIEP16705202.6T priority patent/FI3259345T3/fi
Priority to JP2017543392A priority patent/JP6840084B2/ja
Priority to LTEPPCT/EP2016/053560T priority patent/LT3259345T/lt
Priority to RS20230211A priority patent/RS64062B1/sr
Priority to ES16705202T priority patent/ES2940191T3/es
Priority to PCT/EP2016/053560 priority patent/WO2016131959A1/en
Priority to PL16705202.6T priority patent/PL3259345T3/pl
Priority to EP16705202.6A priority patent/EP3259345B1/en
Priority to PT167052026T priority patent/PT3259345T/pt
Priority to HUE16705202A priority patent/HUE061457T2/hu
Priority to CN201680010458.2A priority patent/CN107532144A/zh
Priority to HRP20230302TT priority patent/HRP20230302T1/hr
Priority to SM20230078T priority patent/SMT202300078T1/it
Priority to CA2986830A priority patent/CA2986830C/en
Publication of EP3059307A1 publication Critical patent/EP3059307A1/en
Publication of EP3059307B1 publication Critical patent/EP3059307B1/en
Application granted granted Critical
Priority to CY20181101344T priority patent/CY1121243T1/el
Priority to JP2020167137A priority patent/JP7132463B2/ja
Publication of EP3059307B2 publication Critical patent/EP3059307B2/en
Priority to US18/512,545 priority patent/US20240150721A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/98—Xeno-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/237—Oncostatin M [OSM]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Definitions

  • the invention relates to the field of cell differentiation and cell therapy.
  • hiPSC human induced pluripotent cells
  • hESC human embryonic stem cells
  • liver transplantation affects millions of people worldwide. To date, liver transplantation is the only curative option when patients with severe metabolic liver disorders. About 25,000 patients are on the waiting lists for liver transplantation in Europe and United States. More than 5500 liver transplantations are performed in Europe per year and inherited metabolic diseases represent 26% of the indications (European Liver Transplant Registry). However, only one third of patients on the liver waiting list can receive a liver transplant each year and the number of patients dying while on the waiting lists for liver transplantation (about 10%) has increased during the last years as a result of the shortage of donor organs.
  • HLCs hepatocyte-like cells
  • mice can engraft, expand in some extend and maintain hepatic functionality after transplantation in the livers of immuno-compromised animals that were chemically-injured, irradiated or genetically-manipulated to give a selective growth advantage to transplanted hepatocytes, such as mice over-expressing the urokinase-type plasminogen activator for inducing a constitutive recipient liver injury and regenerative stimuli [5, 14, 17, 23-25].
  • HLCs have a remarkable ability to regenerate itself from endogenous hepatocytes. Thereby, a temporary support of hepatic metabolic functions by HLCs is sufficient to rescue mice from acute liver failure.
  • HLCs must fully differentiate in vivo and be functional in long-term to express the missing mature hepatic metabolic functions in the diseased animals. So far, successful metabolic correction of an animal modeling a human inherited liver disease in which transplanted HLCs have no selective survival and growth advantage in the recipient livers has not been demonstrated yet.
  • the Gunn rat an animal of CN1, has a natural mutation in UGT1A1 causing a complete loss of UGT1A1 activity and hyperbilirubinemia soon after birth.
  • the total absence of bilirubin conjugates in the bile provides an easy, unequivocal and sensitive read out to evaluate the restoration of UGT1A1 activity.
  • the Gunn rat constitutes an invaluable and convenient model to follow in vivo hepatic cell maturation and therapeutic potential of transplanted hepatocytes.
  • a partial restoration of UGT1A1 activity after hepatocyte transplantation results in a significant metabolic correction [37-39].
  • hepatic differentiation protocol that is in GMP (Good Manufacturing Practices)-compatible.
  • Current protocols of hepatic differentiation commonly contained feeder cells-conditioned medium, serum, animal-derived matrices (such as Matrigel TM ), mouse feeder cells, viral vectors for improving hepatic differentiation, or small molecules that are not available in GMP [15, 34-36]. All of which are sources of unknown factors that render the resulting tissues incompatible with future clinical applications.
  • HLCs Pluripotent stem cells have been intensively investigated as a renewable source of transplantable HLCs.
  • HLCs could treat an inherited metabolic liver disease in absence of any selective growth advantage of transplanted cells over resident rodent hepatocytes is still waiting.
  • previously generated HLCs were produced using protocols that are rendering them unsuitable for clinical applications.
  • laminins such as laminin-521 and laminin-111 have been described as a relevant matrix for cell culture, more particularly for maintaining functional properties of long-term in vitro culture of cells of interest such as pluripotent cells or HLCs but however laminins have never been disclosed nor suggested as useful for inducing and/or improving hepatic differentiation.
  • laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells.
  • pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency.
  • human hepatoblast-like cells can be first generated from pluripotent cells on Matrigel-coated dishes (induction of hepatic differentiation) and then cultured on laminin-111-coated dishes for expanding them for more than 3 months while keeping the potential ability to differentiate into both hepatocyte-like cells and cholangiocyte-like cells [36].
  • the invention relates to the in vitro use of a matrix consisting of a human laminin (LN) for hepatic differentiation.
  • LN human laminin
  • the invention relates to the in vitro use of a matrix consisting of a human LN for inducing and/or improving differentiation of a population of pluripotent cells, or a population of multipotent cells or a population of definitive endoderm (DE) cells into a population of hepatocyte lineage cells.
  • a matrix consisting of a human LN for inducing and/or improving differentiation of a population of pluripotent cells, or a population of multipotent cells or a population of definitive endoderm (DE) cells into a population of hepatocyte lineage cells.
  • the invention relates to an in vitro method for inducing human hepatic differentiation comprising the steps of:
  • the invention relates to an in vitro method for inducing hepatic differentiation comprising the steps of:
  • the present disclosure further describes a population of human hepatoblasts-like cells obtained by the method of the invention.
  • the present disclosure further describes a population of human hepatoblasts-like cells of the disclosure for use in a method of treatment of the human body.
  • the present disclosure further describes a population of human fetal hepatocyte-like cells obtained by the method of the invention.
  • kits for inducing human hepatic differentiation comprising a support coated with a laminin, BMP4 and a member of the fibroblast growth factor (FGF) family such as FGF2 or FGF10.
  • FGF fibroblast growth factor
  • the invention addresses these needs, as it relates to the identification of a chemically defined medium useful for differentiating a population of pluripotent cells or a population of definitive endoderm (DE) cells into a population of hepatocyte lineage cells.
  • the inventors have surprisingly showed that laminin-111 is as efficient as Matrigel for initiating and supporting hepatic differentiation of hiPSC in our culture conditions, but with a recombinant matrix.
  • LN-521 laminin-521
  • HLCs human endoderm
  • the inventors indeed have produced hepatoblasts derived from human pluripotent stem cells (IDHBs) in xeno-free, feeder-free and chemically defined protocols using recombinant laminin-111 (LN-111) as an extracellular matrix for initiating and supporting hepatic differentiation process.
  • IDHBs human pluripotent stem cells
  • LN-111 recombinant laminin-111
  • These IDHBs with a particular set of markers (combination of expressed or non-expressed markers) were transplanted in the liver of the Gunn rat, an animal model for Crigler-Najjar syndrome, which is characterized by high levels of unconjugated bilirubin. Following cell transplantation, they showed significant correction of hyperbilirubinemia, which remained stable throughout the 6-month study with no adverse events.
  • the invention relates to the in vitro use of a matrix consisting of a human laminin (LN) for hepatic differentiation.
  • LN human laminin
  • the invention also relates to the in vitro use of a matrix consisting of a human LN for inducing and/or improving differentiation of a population of pluripotent cells, a population of multipotent cells, or a population of definitive endoderm (DE) cells into a population of hepatocyte lineage cells.
  • a matrix consisting of a human LN for inducing and/or improving differentiation of a population of pluripotent cells, a population of multipotent cells, or a population of definitive endoderm (DE) cells into a population of hepatocyte lineage cells.
  • laminin refers to a protein of a family of heterotrimeric glycoproteins that reside primarily in the basal lamina. They function via binding interactions with neighboring cell receptors on the one side, and by binding to other laminin molecules or other matrix proteins such as collagens, nidogens or proteoglycans.
  • the laminin molecules are also important signaling molecules that can strongly influence cellular behavior and function. Laminins are important in both maintaining cell/tissue phenotype, as well as in promoting cell growth and differentiation in tissue repair and development. Laminins are large, multi-domain proteins, with a common structural organization. The laminin molecule integrates various matrix and cell interactive functions into one molecule.
  • a laminin protein molecule comprises one a-chain subunit, one ⁇ -chain subunit, and one ⁇ -chain subunit, all joined together in a trimer through a coiled-coil domain.
  • the twelve known laminin subunit chains can form at least 15 trimeric laminin types in native tissues. Within the trimeric laminin structures are identifiable domains that possess binding activity towards other laminin and basal lamina molecules, and membrane-bound receptors.
  • laminin encompasses laminin either intact, as separate chains, or as fragments thereof.
  • the term “intact” refers to the protein being composed of all of the domains of the ⁇ -chain, ⁇ -chain, and ⁇ -chain, with the three chains being joined together to form the heterotrimeric structure. The protein is not broken down into separate chains, fragments, or functional domains. For instance, laminin-111 and laminin-521 (as described below) are intact proteins.
  • chain refers to the entirety of the alpha, beta, or gamma chain of the laminin protein.
  • fragment refers to any protein fragment which contains one, two, or three functional domains that possesses binding activity to another molecule or receptor. However, a chain should not be considered a fragment because each chain possesses more than three such domains. Similarly, an intact laminin protein should not be considered a fragment. Examples of functional domains include Domains I, II, III, IV, V, VI, and the G domain.
  • laminin-1 to laminin-15 There exist five different alpha chains, three beta chains and three gamma chains that in human tissues have been found in at least fifteen different combinations. These molecules are termed laminin-1 to laminin-15 based on their historical discovery, but an alternative nomenclature describes the isoforms based on their chain composition, e.g. , laminin-111 (laminin-1) that contains alpha-1, beta-1 and gamma-1 chains.
  • laminin-111 laminin-111
  • laminin-1 contains alpha-1, beta-1 and gamma-1 chains.
  • Four structurally defined family groups of laminins have been identified. The first group of five identified laminin molecules all share the ⁇ 1 and ⁇ 1 chains, and vary by their a-chain composition ( ⁇ 1 to ⁇ 5 chain).
  • the second group of five identified laminin molecules including laminin-521, all share the ⁇ 2 and ⁇ 1 chain, and again vary by their a-chain composition.
  • the third group of identified laminin molecules has one identified member, laminin-332, with a chain composition of ⁇ 3 ⁇ 3 ⁇ 2.
  • the fourth group of identified laminin molecules has one identified member, laminin-213, with the newly identified ⁇ 3 chain ( ⁇ 2 ⁇ 1 ⁇ 3).
  • LN-111 ⁇ 1 ⁇ 1 ⁇ 1 ⁇ 1
  • LN-121 ⁇ 1 ⁇ 2 ⁇ 1
  • LN-211 ⁇ 2 ⁇ 1 ⁇ 1
  • LN-213 ⁇ 2 ⁇ 1 ⁇ 3
  • LN-221 ⁇ 2 ⁇ 2 ⁇ 1
  • LN-311 ⁇ 3 ⁇ 3 ⁇ 1
  • LN-321 ⁇ 3 ⁇ 2 ⁇ 1
  • LN-332 ⁇ 3 ⁇ 3 ⁇ 2 ⁇ 2
  • LN-411 ⁇ 4 ⁇ 1 ⁇ 1 ⁇ 1
  • LN-421 ⁇ 4 ⁇ 2 ⁇ 1
  • LN-423 ⁇ 4 ⁇ 2 ⁇ 3
  • LN-511 ⁇ 5 ⁇ 1 ⁇ 1), LN-521 ( ⁇ 5 ⁇ 2 ⁇ 1), LN-522 ( ⁇ 5 ⁇ 2 ⁇ 2), and LN-523 ( ⁇ 5 ⁇ 2 ⁇ 3).
  • said laminin is selected from the group consisting of laminin-111 (LN-111), laminin-211 (LN-211), laminin-332 (LN-332), laminin-411 (LN-411), laminin-421 (LN-421), laminin-511 (LN-511) and laminin-521 (LN-521).
  • said laminin is a human laminin.
  • said laminin is a human recombinant laminin.
  • said laminin is recombinant human laminin-111 (LN-111) or recombinant human laminin-521 (LN-521).
  • polypeptide refers to a polypeptide which is produced by expression from an encoding nucleic acid molecule.
  • Systems for cloning and expression of a polypeptide in a variety of different host cells are well known.
  • the polypeptide When expressed in recombinant form, the polypeptide is preferably generated by expression from an encoding nucleic acid in a host cell.
  • a host cell Any host cell may be used, depending upon the individual requirements of a particular system. Suitable host cells include bacteria mammalian cells, plant cells, yeast and baculovirus systems.
  • Recombinant human laminins such as recombinant human LN-111 or LN-521 can be purchased from Biolamina, Sundbyberg, Sweden.
  • laminin is coated to the support such as a plate from 0,5 to 50 micrograms per milliliter ( ⁇ g/mL), preferably from 1 to 10 ⁇ g/mL, more preferably at 5 ⁇ g/mL.
  • matrix refers to a component/material (natural, synthetic or a combination thereof) forming a polymeric network which provides to in vitro cultured cells (e.g. , on culture vessel such as flat plasticware) an in vivo like morphology and physiologically relevant environments for more realistic cell biology and better intercellular interactions for cell culture, facilitating cell attachment, growth, differentiation
  • the matrix comprises a laminin such as recombinant human laminin-111 (LN-111) or recombinant human laminin-521 (LN-521) or a mixture thereof.
  • a laminin such as recombinant human laminin-111 (LN-111) or recombinant human laminin-521 (LN-521) or a mixture thereof.
  • the matrix comprises a mixture of a laminin and another component (such as matrix proteins including collagen I and fibronectin).
  • the term "population” refers to a population of cells, wherein the majority (e.g. , at least about 50%, preferably at least about 60%, more preferably at least about 70%, and even more preferably at least about 80%) of the total number of cells have the specified characteristics of the cells of interest for at least one of the markers of interest (e.g. , a population of human hepatocyte-like cells comprises at least about 60%, preferably at least about 70%, more preferably at least about 80% of cells which have the hepatic functions and which express the markers typically expressed by human hepatocyte-like cells listed below such as for instance hepatocyte nuclear factor 4alpha (HNF4 ⁇ )).
  • HNF4 ⁇ hepatocyte nuclear factor 4alpha
  • the term "marker” refers to a protein, glycoprotein, or other molecule expressed on the surface of a cell or into a cell, and which can be used to help identify the cell.
  • a marker can generally be detected by conventional methods. Specific, non-limiting examples of methods that can be used for the detection of a cell surface marker are immunocytochemistry, fluorescence activated cell sorting (FACS), and enzymatic analysis but also RT-PCR and molecular biology methods to detect mRNA of the protein.
  • FACS fluorescence activated cell sorting
  • pluripotent refers to cells with the ability to give rise to progeny that can undergo differentiation, under appropriate conditions, into cell types that collectively exhibit characteristics associated with cell lineages from the three germ layers (endoderm, mesoderm, and ectoderm). Pluripotent stem cells can contribute to tissues of a prenatal, postnatal or adult organism. A standard art-accepted test, such as the ability to form a teratoma in 8-12-week-old SCID mice, can be used to establish the pluripotency of a cell population. However, identification of various pluripotent stem cell characteristics can also be used to identify pluripotent cells.
  • the pluripotent stem cells are human pluripotent stem cells.
  • human pluripotent stem cells may express at least some, and optionally all, of the markers from the following non-limiting list: SSEA-3, SSEA-4, TRA-I -60, TRA-I -81, TRA-2-49/6E, ALP, Sox 2, E-cadherin, UTF-I, Oct4, Lin28, Rexl, and Nanog.
  • the human pluripotent stem cells are human induced pluripotent stem cells (hiPSCs).
  • induced pluripotent stem cell refers to a pluripotent stem cell artificially derived from a non-pluripotent cell.
  • a non-pluripotent cell can be a cell of lesser potency to self-renew and differentiate than a pluripotent stem cell.
  • Cells of lesser potency can be, but are not limited to, somatic stem cells, tissue specific progenitor cells, primary or secondary cells.
  • iPSCs have been reproducibly obtained by reprogramming different cell types by forced expression of the OCT4, SOX2, c-MYC and KLF4 transcription factor cocktail or by an alternative combination of factors, substituting KLF4 and c-MYC by or adding NANOG and LIN28, or any methods known from the skilled man to improve reprogramming process (carrying out the use of small molecules such as DNA methyltransferase (DNMT) inhibitors, miRNAs, etc.).
  • DNMT DNA methyltransferase
  • reprogramming refers to the process of changing the fate of a target cell into that of a different cell type, caused by the expression of a small set of factors (or reprogramming factors) in the target cells.
  • Expression vectors for ectopic expression of the reprogramming factors may be, for example, plasmid vector, cosmid vector, bacterial artificial chromosome (BAC) vector, transposon-based vector (such as PiggyBac) or viral vector.
  • plasmid vector cosmid vector
  • BAC bacterial artificial chromosome
  • transposon-based vector such as PiggyBac
  • the reprogramming factors for example, Oct4, Sox2, Klf4 and c-Myc, or corresponding coding DNA or RNA
  • the reprogramming factors are introduced into the target cells without integration of exogenous genetic material in the host DNA, i.e., without introduction of the nucleotide sequence in the cell's genome.
  • An expression vector such as a plasmid vector can be delivered into said cells for ectopic expression of the reprogramming factor, in the form of naked DNA.
  • RNAs coding for said reprogramming factors either chemically modified or not, can be introduced into the cells to reprogram them (see for example Warren L, et al, 2010, Cell Stem Cell. Nov 5;7(5):618-30 ).
  • Other expression vectors have been described for example in WO 2009115295 .
  • the hiPSCs are derived from cells obtained from a healthy subject. In another embodiment, the hiPSCs are derived from cells obtained from a subject with a liver disease such as an inherited metabolic liver disease and the hepatocyte-like cells display a disease phenotype.
  • a population of hepatocyte lineage cells of interest may be obtained from the differentiation of multipotent cells, such as mesenchymal stem cells, on a matrix for hepatic differentiation constituted of a laminin of the invention.
  • multipotent refers to cells capable of differentiating into at least two terminally differentiated cell types.
  • mesenchymal stem cells generally refers to stromal cells found in a differentiated (specialized) tissue and that are capable of making identical copies of themselves (self-renewal) for the lifetime of the organism and have multipotent differentiation potential (such as differentiation into osteoblasts, adipocytes, chondroblasts).
  • human mesenchymal stem cells that can be used in the context of the present invention thus include any suitable human multipotent stem cells (i.e., cells with an ability for self-renewal and for multipotency) derived from any suitable tissue using any appropriate isolation method.
  • human mesenchymal stem cells that can be used in the methods of the present invention include, but are not limited to, adult multilineage inducible (MIAMI) cells ( D'Ippolito et al., J. Cell Sci., 2004, 117: 2971-2981 ), MAPC (also known as MPC) ( Reyes al., Blood, 2001, 98: 2615-2625 ), cord blood derived stem cells ( Kögler G et al., J. Exp. Med., 2004, 200(2): 123-135 ), mesoangioblasts ( Sampaolesi M et al., Nature, 2006, 444(7119): 574-579 ; Dellavalle A et al., Nat.
  • MIAMI adult multilineage inducible
  • a population of hepatocyte lineage cells may be obtained from the differentiation of cells isolated from adult human livers (e.g. , hepatocyte progenitor cells) on a matrix for hepatic differentiation constituted of a laminin. Still alternatively, a population of hepatocyte lineage cells of interest may be obtained from the conversion of somatic cells such as fibroblasts on a matrix for hepatic differentiation constituted of a laminin.
  • hepatocyte lineage cells or “hepatocyte-like cells” (HLCs) refer to cells obtained by differentiating pluripotent cells, endodermal cells or other kind of cells such as multipotent cells in the manner described.
  • the differentiated cells have at least one of a variety of distinguishing phenotypic characteristics of known hepatocyte progenitors, hepatoblasts, foetal and mature hepatocytes, as provided later in this disclosure.
  • HSCs hepatocyte-like cells
  • Hepatocyte lineage cells express hepatic markers including but not limited to hepatocyte nuclear factor 4alpha (HNF4 ⁇ ), albumin (ALB), alpha-fetoprotein (AFP), cytochrome P450 and cytokeratin 19 (CK19).
  • HNF4 ⁇ hepatocyte nuclear factor 4alpha
  • ALB albumin
  • AFP alpha-fetoprotein
  • CK19 cytokeratin 19
  • Determination of the expression level of markers including hepatic markers may be performed by a variety of techniques.
  • the expression level as determined is a relative expression level.
  • the determination comprises contacting the biological sample with selective reagents such as probes or ligands, and thereby detecting the presence, or measuring the amount, of nucleic acids or polypeptides of interest originally in said biological sample. Contacting may be performed in any suitable device, such as a plate, microtiter dish, test tube, well, glass, column, and so forth.
  • the contacting is performed on a substrate coated with the reagent, such as a nucleic acid array or a specific ligand array.
  • the substrate may be a solid or semi-solid substrate such as any suitable support comprising glass, plastic, nylon, paper, metal, polymers and the like.
  • the substrate may be of various forms and sizes, such as a slide, a membrane, a bead, a column, a gel, etc.
  • the contacting may be made under any condition suitable for a detectable complex, such as a nucleic acid hybrid or an antibody-antigen complex, to be formed between the reagent and the nucleic acids or polypeptides of the biological sample.
  • the expression level of the biomarkers genes may be determined by determining the quantity of mRNA.
  • the nucleic acid contained in the cells of interest such as the HLCs of the invention is first extracted according to standard methods, for example using lytic enzymes or chemical solutions or extracted by nucleic-acid-binding resins following the manufacturer's instructions.
  • the extracted mRNA is then detected by hybridization (e.g., Northern blot analysis) and/or amplification ( e.g., RT-PCR).
  • Quantitative or semi-quantitative RT-PCR is preferred. Real-time quantitative or semi-quantitative RT-PCR is particularly advantageous.
  • the expression level of the biomarkers genes may be determined by determining of the quantity of protein encoded by said genes.
  • Such methods comprise contacting the biological sample with a binding partner capable of selectively interacting with the protein present in said sample.
  • the binding partner is generally an antibody that may be polyclonal or monoclonal, preferably monoclonal.
  • the level of a biomarker protein such as HNF4 ⁇ , ALB, AFP and CK19 may be measured by using standard electrophoretic and immunodiagnostic techniques, including immunoassays such as competition, direct reaction, or sandwich type assays.
  • immunoassays include, but are not limited to, Western blots; agglutination tests; enzyme- labeled and mediated immunoassays, such as ELISAs; biotin/avidin type assays; radioimmunoassays; immunoelectrophoresis; immunoprecipitation.
  • the cell culture conditions may include one or more additional components to provide a supportive environment during directed differentiation into the target differentiated cell type (e.g., hepatocyte lineage cells).
  • the methods for obtaining a population of differentiated target cells additionally include a step of inducing differentiation. Inducing differentiation may be accomplished by changing the composition of growth factors in the culture medium at one or more stages of differentiation as described below.
  • the disclosure further describes a method for inducing human hepatic differentiation comprising the steps of:
  • the disclosure also describes a method for obtaining human hepatoblast-like cells comprising the steps of:
  • the term "definitive endoderm cells” refers to cells expressing characteristic biochemical markers, including but not limited to Sox 17 and FoxA2 and not expressing nanog.
  • hepatoblast-like cells HB
  • hepatic progenitor cells are interchangeably and refer to cells expressing characteristic biochemical markers, including but not limited to hepatocyte nuclear factor 4 alpha (HNF4 ⁇ ), cytokeratin 19 (CK19) and cytochrome P450 3A7 (CYP3A7), and not expressing or substantially not expressing alpha-fetoprotein (AFP) and not expressing albumin (ALB), alpha-1 antitrypsin (AAT), cytochrome P450 3A7 (CYP3A7) and uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1).
  • HNF4 ⁇ hepatocyte nuclear factor 4 alpha
  • CK19 cytokeratin 19
  • CYP3A7 cytochrome P450 3A7
  • UDP uridine diphosphate
  • the term "substantially not” refers to a population of hepatoblast-like cells which express a low level of a protein of interest such as AFP. Accordingly, such cells may only express a low quantity or amount of AFP protein undetectable by ELISA, such as several picograms (pg) which is below the limit of detection (LOD) for AFP by ELISA. However, it should be further noted that a low quantity of AFP mRNA may be detected by RT-PCR (but such quantity is insufficient for detecting in fine expression of AFP protein).
  • hepatic induction medium or "culture medium inducing hepatic differentiation” refer to a culture medium that is capable of inducing differentiation of definitive endoderm into hepatoblast-like cells (and thus capable of inducing the expression of hepatic markers such as HNF4 ⁇ , CK19 and CYP3A7).
  • culture medium refers to any medium capable of supporting the growth and the differentiation of definitive endoderm cells into hepatic progenitor cells.
  • Preferred media formulations that will support the growth and the differentiation of definitive endoderm cells into hepatic progenitor cells include chemically defined medium (CDM).
  • CDM chemically defined medium
  • serum-free refers to a culture medium containing no added serum.
  • feeder-free refers to culture medium containing no added feeder cells.
  • the culture medium used by the invention may be a water-based medium that includes a combination of substances such as salts, nutrients, minerals, vitamins, amino acids, nucleic acids, proteins such as cytokines, growth factors and hormones, all of which are needed for cell survival.
  • a culture medium according to the invention may be a synthetic tissue culture medium such as the RPMI (Roswell Park Memorial Institute medium) or the CMRL-1066 (Connaught Medical Research Laboratory) for human use, supplemented with the needed additives if required as is further described below (Section Examples) such as B27.
  • the B-27 supplement contains, amongst other constituents, SOD, catalase and other anti-oxidants (GSH), and unique fatty acids, such as linoleic acid, linolenic acid, lipoic acids.
  • the step of culturing DE cells with the hepatic induction medium shall be carried out for the necessary time required for the production of hepatoblast-like cells.
  • the duration of this culture step may be determined easily by one of skill in the art. For instance, during the culture the person skilled in the art can monitor the cultured cells for the absence of at least one of expression of markers only expressed by definitive endoderm (DE) cells (e.g., Sox17 and FoxA2) and/or for the expression of markers specifically expressed by hepatoblast-like cells (e.g., HNF4 ⁇ , CK19, CYP3A7).
  • DE definitive endoderm
  • hepatoblast-like cells e.g., HNF4 ⁇ , CK19, CYP3A7.
  • culturing with the hepatic induction medium can be stopped. Monitoring of these markers can be performed using for instance RT-PCR analysis of RNA extracted from cultured cells with specific primers, immunofluorescence analysis with antibodies specific of the markers and FACS or any method to detect the mRNA corresponding to the proteins.
  • the step ii) may be carried out for 3 to 10 days, preferably 6 days.
  • the culture medium of the invention can be renewed, partly or totally, at regular intervals.
  • the culture medium of the invention can be replaced with fresh culture medium of the invention every other day, for 6 days.
  • the hepatoblast-like cells produced by the above method may be isolated and/or purified using any suitable method, for example FACS.
  • FGF family growth factor refers to any naturally occurring substance (e.g., a protein) capable of stimulating cellular growth, proliferation and cellular differentiation by binding to one fibroblast growth factor receptor (FGFR). By binding to one FGFR, the substance increases for example the tyrosine phosphorylation of said receptor.
  • FGFR fibroblast growth factor receptor
  • the hepatic induction medium is a chemically defined medium comprising bone morphogenetic protein 4 (BMP4) and a FGF.
  • BMP4 bone morphogenetic protein 4
  • the hepatic induction medium is a chemically defined medium comprising bone morphogenetic protein 4 (BMP4) and family growth factor 10 (FGF10).
  • FGF10 The naturally occurring human FGF10 protein has an amino acid sequence as shown in Uniprot Accession number 015520.
  • FGF10 is added to the culture medium of the invention in a concentration ranging from 1 to 50 ng/mL, preferably at about 10 ng/mL.
  • FGF10 can be purchased from Peprotech or Miltenyi Biotec.
  • BMP4 The naturally occurring human BMP4 protein has an amino acid sequence as shown in Uniprot Accession number P12644.
  • BMP4 is added to the culture medium of the invention in a concentration ranging from 1 to 50 ng/mL, preferably at about 10 ng/mL.
  • BMP4 can be purchased from R&D systems.
  • the hepatic induction medium is a chemically defined medium comprising bone morphogenetic protein 4 (BMP4) and FGF2 (also known as basic fibroblast growth factor).
  • BMP4 bone morphogenetic protein 4
  • FGF2 also known as basic fibroblast growth factor
  • FGF2 The naturally occurring human FGF2 protein has an amino acid sequence as shown in Uniprot Accession number P09038.
  • FGF2 is added to the culture medium of the invention in a concentration ranging from 1 to 50 ng/mL, preferably at about 10 ng/mL.
  • FGF2 can be purchased from Peprotech or Miltenyi Biotec.
  • culturing the population of DE cells may additionally include passaging the population of DE cells prior to or during the process of differentiation.
  • the process of passaging the population of cells may be repeated one or more times, and may include dissociating cells supported by the attachment matrix, diluting the dissociated cells in media.
  • the step ii) may further comprise a step of passaging at least one time and/or cell counting.
  • cells may be treated with a ROCK inhibitor 4 hours prior to dissociation and 24 hours post plating.
  • Rho-associated protein kinase (ROCK) inhibitor refers to a compound (natural or synthetic) which inhibits ROCK1 and/or ROCK2 activity such as kinase activity.
  • the ROCK inhibitor is Y27632 ( Watanabe et al. Nature Biotechnology 25, 681 - 686 (2007 )).
  • the concentration of Y27632 in the culture medium may be from 1 to 100 ng/mL, preferably about 10 ng/mL.
  • said laminin is selected from the group consisting of LN-111, LN-211, LN-332, LN-411, LN-421, LN-511 and LN-521.
  • said laminin is a human laminin.
  • said laminin is a human recombinant laminin.
  • laminin is coated to the support such as a plate from 0.5 to 50 micrograms per milliliter ( ⁇ g/mL), preferably from 1 to 10 ⁇ g/mL, more preferably at 5 ⁇ g/mL.
  • the support is typically a surface in a culture vessel.
  • the support is selected from the group consisting of a plate, a slide, a flask, and the like.
  • the support has at least a portion of a surface coated with a matrix of the invention such as human recombinant LN-111 or human recombinant LN-521.
  • the disclosure also describes a method for inducing human hepatic differentiation comprising the steps of:
  • the disclosure also describes a method for obtaining human DE cells comprising the steps of:
  • the disclosure also describes a method for inducing human hepatic differentiation comprising the steps of:
  • the disclosure also describes a method for obtaining human hepatoblast-like cells comprising the steps of:
  • endoderm induction medium or "culture medium inducing endoderm differentiation” refer to a culture medium that is capable of inducing differentiation of pluripotent stem cells into definitive endoderm cells (and thus capable of inducing the expression of endoderm markers such as Sox 17 and FoxA2).
  • the endoderm induction medium is a chemically defined medium comprising at least Activin A and optionally WNT3A.
  • Activin A is well known in the art and is a dimeric polypeptide which exerts a range of cellular effects via stimulation of the Activin/Nodal pathway ( Vallier et al., Cell Science 118:4495-4509 (2005 )).
  • the naturally occurring human activin A protein has an amino acid sequence as shown in GeneBank Accession number NP_002183. Activin is readily available from commercial sources ( e.g., Stemgent Inc. MA USA or Miltenyi Biotec).
  • the concentration of Activin A in the culture medium may be from 10 to 1000 ng/mL, preferably about 100 ng/mL.
  • the naturally occurring human WNT3A protein has an amino acid sequence as shown in Uniprot Accession number P56704.
  • the concentration of WNT3A in the culture medium may contain 10 to 100 ng/mL WNT3A, preferably about 50 ng/mL.
  • WNT3A can be purchased from Miltenyi Biotec.
  • the step of culturing pluripotent stem cells with the endoderm induction medium shall be carried out for the necessary time required for the production of definitive endoderm (DE).
  • the duration of this culture step may be determined easily by one of skill in the art. For instance, during the culture the person skilled in the art can monitor the cultured cells for the expression of markers specifically expressed by definitive endoderm (DE) (e.g., Sox 17 and FoxA2). When expression of one or several markers specific of DE cells is detected, culturing with the hepatic induction medium can be stopped.
  • Monitoring of these markers can be performed using for instance RT-PCR analysis of RNA extracted from cultured cells with specific primers, immunofluorescence analysis with antibodies specific of the markers, ELISA and FACS or any method to detect the RNA/protein/activity corresponding to the specific marker.
  • the step ii) may be carried out for 1 to 10 days, preferably 5 days.
  • the culture medium of the invention can be renewed, partly or totally, at regular intervals.
  • the culture medium of the invention can be replaced with fresh culture medium of the invention every other day, for 5 days.
  • the hepatoblast-like cells produced by the above method may be isolated and/or purified using any suitable method, for example FACS.
  • said laminin is selected from the group consisting of LN-111, LN-211, LN-332, LN-411, LN-421, LN-511 and LN-521.
  • said laminin is a human laminin.
  • said laminin is a human recombinant laminin.
  • laminin is coated to the support such as a plate from 0.5 to 50 micrograms per milliliter ( ⁇ g/mL), preferably from 1 to 10 ⁇ g/mL, more preferably at 5 ⁇ g/mL.
  • the support is typically a surface in a culture vessel.
  • the support is selected from the group consisting of a plate, a slide, a flask, and the like.
  • the support has at least a portion of a surface coated with a matrix of the invention such as human recombinant LN-111 or human recombinant LN-521.
  • the invention relates to an in vitro method for obtaining human fetal hepatocytes cells comprising the steps of:
  • fetal hepatocyte-like cells or “differentiated hepatoblasts” are used herein interchangeably and refer to cells expressing characteristic biochemical markers, including but not limited to HNF4 ⁇ , CYP3A7, AFP and CK19, and may expressed some mature hepatic proteins, including but not limited to ALB, AAT, UGT1A1, and cytochrome P450 3A4 (CYP3A4).
  • characteristic biochemical markers including but not limited to HNF4 ⁇ , CYP3A7, AFP and CK19
  • CYP3A4 cytochrome P450 3A4
  • hepatic maturation medium or "culture medium stimulating hepatic maturation” refer to a culture medium that is capable of inducing maturation of hepatoblast-like cells to fetal hepatocyte-like cells.
  • the hepatic induction medium is a chemically defined medium comprising HGF and OSM.
  • HGF hepatic growth factor
  • hepatic growth factor refers to a growth factor which regulates cell growth, cell motility, and morphogenesis by activating a tyrosine kinase signaling cascade after binding to the proto-oncogenic c-MET receptor.
  • the naturally occurring human HGF protein has an amino acid sequence as shown in Uniprot Accession number P14210.
  • HGF is added to the hepatic maturation medium at a concentration ranging from 1 to 100 ng/mL, preferably from 5 to 50 ng/mL, and even more preferably about 20 ng/mL.
  • HGF can be purchased from Peprotech.
  • oncostatin M refers to a cytokine which inhibits the proliferation of a number of tumor cell lines.
  • OSM oncostatin M
  • the naturally occurring human OSM protein has an amino acid sequence as shown in Uniprot Accession number P13725.
  • Oncostatin M is added to the hepatic maturation medium at a concentration ranging from 1 to 100 ng/mL, preferably from 5 to 50 ng/mL, and even more preferably about 20 ng/mL.
  • OSM can be purchased from Miltenyi Biotec.
  • the step of culturing hepatoblast-like cells with the hepatic maturation medium shall be carried out for the necessary time required for the production of fetal hepatocyte-like cells.
  • the duration of this culture step may be determined easily by one of skill in the art. For instance, during the culture the person skilled in the art can monitor the cultured cells for the absence of expression of specific markers of pluripotent stem cells (e.g., Sox 2 and Nanog), absence of expression of specific markers of definitive endoderm (DE) (e.g., Sox 17 and FoxA2), expression of specific markers of hepatoblasts and/or for the expression of markers specifically expressed by fetal hepatocyte-like cells (e.g., AFP and ALB).
  • specific markers of pluripotent stem cells e.g., Sox 2 and Nanog
  • DE definitive endoderm
  • AFP and ALB fetal hepatocyte-like cells
  • culturing with the hepatic maturation medium can be stopped. Monitoring of these markers can be performed using for instance RT-PCR analysis of RNA extracted from cultured cells with specific primers, immunofluorescence analysis with antibodies specific of the markers, ELISA and FACS or any method to detect the RNA/protein/activity corresponding to the specific marker.
  • the step ii) may be carried out for 3 to 60 days, preferably 30 days.
  • the culture medium of the invention can be renewed, partly or totally, at regular intervals.
  • the culture medium of the invention can be replaced with fresh culture medium of the invention every other day, for 30 days.
  • the fetal hepatocyte-like cells produced by the above method may be isolated and/or purified using any suitable method, for example FACS.
  • said laminin is selected from the group consisting of LN-111, LN-211, LN-332, LN-411, LN-421, LN-511 and LN-521.
  • said laminin is a human laminin.
  • said laminin is a human recombinant laminin.
  • laminin is coated to the support such as a plate from 0.5 to 50 micrograms per milliliter ( ⁇ g/mL), preferably from 1 to 10 ⁇ g/mL, more preferably at 5 ⁇ g/mL.
  • the support is typically a surface in a culture vessel.
  • the support is selected from the group consisting of a plate, a slide, a flask, and the like.
  • the support has at least a portion of a surface coated with a matrix of the invention such as human recombinant LN-111 or human recombinant LN-521.
  • the disclosure further describes a population of human hepatoblast-like cells obtained by a method as defined above.
  • the disclosure further describes a population of human hepatoblast-like cells obtained by a method as defined above, wherein said cells express hepatocyte nuclear factor 4alpha (HNF4 ⁇ ) and do not express or substantially not express alpha-fetoprotein (AFP).
  • HNF4 ⁇ hepatocyte nuclear factor 4alpha
  • AFP alpha-fetoprotein
  • the disclosure further describes a population of human hepatoblast-like cells obtained by a method as defined above, wherein said cells express HNF4 ⁇ , cytokeratin 19 (CK19) and cytochrome P450 3A7 (CYP3A7) and do not express or substantially not express AFP, albumin (ALB), alpha-1 antitrypsin (AAT), cytochrome P450 3A4 (CYP3A4), uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1).
  • the disclosure further describes a population of human fetal hepatocytes cells obtained by a method as defined above.
  • the disclosure further describes a population of human fetal hepatocyte-like cells obtained by a method as defined above, wherein said cells express HNF4 ⁇ , CK19, CYP3A7, AFP, ALB, AAT and UGT1A1, and cytochrome P450 3A4 (CYP3A4).
  • the human hepatocyte-like cells i.e., hepatoblasts or fetal hepatocyte-like cells or mature hepatocytes
  • display a normal phenotype i.e., hepatoblasts or fetal hepatocyte-like cells or mature hepatocytes
  • the human hepatoblast-like cells i.e., hepatoblasts or fetal hepatocyte-like cells
  • display a genetic mutation in particular genetic mutation that affects key protein within human hepatoblast-like cells and which is associated with a liver disease.
  • the genetic mutation or defect which is responsible for the disease phenotype may be corrected in vitro or ex vivo.
  • Various techniques are available to correct genetic mutations or defects in isolated mammalian cells.
  • the term "genetically modified" indicates that the human hepatocyte-like cells (i.e., hepatoblasts or fetal hepatocyte-like cells or mature hepatocytes) comprise a nucleic acid molecule not naturally present in non-modified human early hepatic progenitor cells, or a nucleic acid molecule present in a non-natural state in said human early hepatic progenitor cells (e.g., amplified).
  • the nucleic acid molecule may have been introduced into said cells or into an ancestor thereof (such as iPS which contains a liver disease associated genetic mutation).
  • a number of approaches can be used to genetically modify human hepatocyte-like cells, such as virus-mediated gene delivery, non-virus-mediated gene delivery, naked DNA, physical treatments, etc.
  • the nucleic acid is usually incorporated into a vector, such as a recombinant virus, a plasmid, phage, episome, artificial chromosome, etc.
  • the hepatocyte-like cells are genetically modified using a viral vector (or a recombinant virus) or a non-viral method.
  • the heterologous nucleic acid is, for example, introduced into a recombinant virus which is then used to infect human hepatocyte-like cells (HLCs).
  • HSCs hepatocyte-like cells
  • Different types of recombinant viruses can be used, in particular lentivirus.
  • said lentivirus encodes an immortalizing protein, such as SV40T, hTERT, CDK4, etc.
  • said lentivirus encodes a wild-type protein (such a protein usually displaying a disease associated genetic mutation in patients suffering from a liver disease) such as wild-type ⁇ 1-antitrypsin (AAT) protein or UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1).
  • AAT wild-type ⁇ 1-antitrypsin
  • UDP glucuronosyltransferase 1 family
  • UDT1A1 polypeptide A1
  • the nucleic acid sequence encoding the protein of interest is operatively linked to a promoter.
  • said lentivirus encodes a reporter protein or marker protein.
  • Said marker protein which may be a fluorescent protein or a cell surface expressed protein, permits the rapid identification and isolation of human hepatocyte-like cells (HLCs) of interest.
  • the marker protein may, for instance, be selected from the group consisting of:
  • operably linked means that the components described are in a relationship permitting them to function in their intended manner.
  • a nucleic acid sequence is “operably linked” when placed into a functional relationship with another sequence nucleic sequence.
  • a promoter is “operably linked” to a coding sequence if the promoter causes the transcription of the coding sequence.
  • operably linked means the linked nucleic acid sequences are contiguous.
  • promoter refers to a DNA sequence that determines the site of transcription initiation for an RNA polymerase.
  • a promoter may comprise a RNA polymerase III promoter that can provide high levels of constitutive expression across a variety of cell types and will be sufficient to direct the transcription of a distally located sequence, which is a sequence linked to the 3' end of the promoter sequence in a cell.
  • Suitable promoters include, for example, constitutive, regulated, tissue-specific or ubiquitous promoters, which may be of cellular, viral or synthetic origin.
  • the promoter is a constitutive promoter such as human elongation factor-1 alpha (EF-1 alpha), etc.
  • the promoter is a liver-specific promoter such as, human 1-antitrypsin, albumin, etc.
  • the promoter is an endogenous sequence (constitutive or specific).
  • the protein of interest is linked to the endogenous promoter by a genome editing technology based on the use of an artificial nuclease (ex: CRISPR/cas, ZFNs, TALENs).
  • gene modification of human hepatoblast-like cells is performed by genome editing technology to modify the endogenous gene sequence.
  • hepatocyte-lineage cells are the target of disease in a variety of conditions often known as “liver diseases” (also referred as “pathology associated with hepatic damage "). These terms refer to any disease or clinical condition characterized by hepatic damage, injury, dysfunction, defect, or abnormality. Thus, the term encompasses, for example, injuries, degenerative diseases and genetic diseases.
  • liver diseases are becoming one of the most common causes of mortality in developing countries.
  • This group of diseases which targets hepatocyte-lineage cells such as hepatocytes which represent the dominant liver cells encompasses inherited metabolic disorders (such as Crigler-Najjar Syndrome type I, Glycogen storage disease, Urea cycle defects, familial hypercholesterolemia, tyrosinemia and Wilson's Disease), chronic liver failure as well as acute liver failure which may be caused by viral infection (in particular infection with HBV or HCV), toxic (alcohol) and drugs, or autoimmune disorder (Autoimmune Chronic Hepatitis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis).
  • metabolic disorders such as Crigler-Najjar Syndrome type I, Glycogen storage disease, Urea cycle defects, familial hypercholesterolemia, tyrosinemia and Wilson's Disease
  • chronic liver failure as well as acute liver failure which may be caused by viral infection (in particular infection with HBV or HCV), toxic (alcohol) and drugs,
  • the disclosure further describes a pharmaceutical composition
  • a pharmaceutical composition comprising the population of human hepatoblast-like cells (e.g ., hepatoblast-like cells or fetal hepatocyte-like cells) according to the disclosure.
  • the pharmaceutical composition may generally include one or more pharmaceutically acceptable and/or approved carriers, additives, antibiotics, preservatives, adjuvants, diluents, solvent and/or stabilizers.
  • auxiliary substances can be water, saline, glycerol, ethanol, wetting or emulsifying agents, pH buffering substances, or the like.
  • Suitable carriers are typically large, slowly metabolized molecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates, or the like.
  • This pharmaceutical composition can contain additional additives such as mannitol, dextran, sugar, glycine, lactose or polyvinylpyrrolidone or other additives such as antioxidants or inert gas, stabilizers or recombinant proteins (e. g. human serum albumin) or vitamins suitable for in vivo administration.
  • additional additives such as mannitol, dextran, sugar, glycine, lactose or polyvinylpyrrolidone or other additives such as antioxidants or inert gas, stabilizers or recombinant proteins (e. g. human serum albumin) or vitamins suitable for in vivo administration.
  • pharmaceutically acceptable refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate.
  • a pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • the human hepatocyte-like cells i.e., hepatoblasts or fetal hepatocyte-like cells obtained from healthy or diseased patients may also be used advantageously for screening applications in the pharmaceutical industry.
  • Such screening tests can be used to search for new drugs with clinical applications or for toxicology tests evaluation of hepatotoxicity of compounds such as pharmaceutical candidate compounds.
  • the human hepatoblast-like cells according to the disclosure may for instance be useful for generating cellular models of liver diseases as described above.
  • the disclosure further describes a method of screening for a compound useful in the treatment of a liver disease comprising the steps of:
  • hepatotoxic refers to a compound which provokes a decrease in the survival of hepatic progenitor cells. A compound is deemed to have a hepatotoxic effect if the number of viable cells cultured in the presence of said compound is lower than the number of viable cells cultured in the absence of said compound.
  • hepatoprotective refers to a compound which results in an increase survival of the hepatic progenitor cells. A compound is deemed to have a hepatoprotective effect if the number of viable cells cultured in the presence of said compound is higher than the number of viable cells cultured in the absence of said compound.
  • the hepatoprotective effect can be assayed in the absence of hepatotrophic factors.
  • the hepatoprotective effect can be assayed in the presence of a known hepatotoxic drug.
  • Known hepatotoxic drugs include, but are not limited to amiodarone, methotrexate, nitrofurantoin.
  • hepatoproliferative refers to a compound which results in an increase proliferation of the hepatic progenitor cells.
  • a compound is deemed to have a hepatoproliferative effect if the number of proliferative cells cultured in the presence of said compound is higher than the number of viable cells cultured in the absence of said compound.
  • the hepatoproliferative effect can be assayed in the absence of growth factors.
  • the test compound may be selected from the group consisting of peptides, proteins, peptidomimetics, small organic molecules, aptamers or nucleic acids.
  • the test compound according to the disclosure may be selected from a library of compounds previously synthesised, or a library of compounds for which the structure is determined in a database, or from a library of compounds that have been synthesised de novo.
  • the test compound may be selected from small organic molecules.
  • small organic molecule refers to a molecule of size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e.g., proteins, nucleic acids, etc.); preferred small organic molecules range in size up to 2000 Da, and most preferably up to about 1000 Da.
  • test compound may be selected from the group consisting of a nucleic acids library, including but not limited to shRNA, miRNA, mRNA.
  • hepatoblast-like cells which may be derived from human ES or iPS further makes it possible to design in vitro and in vivo models of human liver diseases and hepatotropic viruses, in particular hepatitis B or C. More specifically an in vivo model of human liver diseases and hepatotropic viruses may be provided by repopulating the liver of a non-human mammal with human early hepatic progenitor cells.
  • the disclosure further describes the use of human hepatocyte-like cells (i.e., hepatoblast-like cells or fetal hepatocyte-like cells) obtained by a method according to the invention for producing a non-human mammalian host which comprises functional human hepatocytes.
  • human hepatocyte-like cells i.e., hepatoblast-like cells or fetal hepatocyte-like cells
  • a suitable method to produce a chimeric non-human mammal which comprises functional human hepatocytes may comprise the step consisting of injecting into the liver of said non-human mammal human hepatocyte-like cells (i.e., hepatoblast-like cells or fetal hepatocyte-like cells) according to the disclosure.
  • the non-human mammal may receive an antimacrophage treatment to control non-adaptive defense. This may be carried out for instance by administering dichloromethylene diphosphonate, e.g., by intraperitoneal injection of liposome-encapsulated dichloromethylene diphosphonate.
  • liver regeneration before cell injection may be carried out for instance by performing a livery injury (e.g., partial hepatectomy, chemical embolization, liver irradiation, hepatotoxins, transgene) or by administrating any compounds stimulating hepatocyte proliferation (hepatocyte growth factor, T3 hormone).
  • a livery injury e.g., partial hepatectomy, chemical embolization, liver irradiation, hepatotoxins, transgene
  • any compounds stimulating hepatocyte proliferation hepatocyte growth factor, T3 hormone
  • engraftment of the HLCs may be also favoured by inhibiting the proliferative potential of endogenous hepatocytes in a regenerating liver (young animals or injured liver). This may be carried out for instance by administering retrorsine (intraperitoneal injection), mitomycin C (intraperitoneal injection) or propranolol hydrochloride (drinking water). Finally, engraftment of the HLCs may be favoured by administrating vasodilator compounds. This may be carried out for instance by administering glyceryl trinitrate.
  • the disclosure further describes a chimeric non-human mammal which comprises functional human hepatocytes obtained or obtainable by the method of the invention.
  • the non-human mammal of the disclosure may be any non-primate mammal into which human hepatocytes may be introduced and maintained. This includes, but is not limited to, horses, sheep, cows, cats, dogs, rats, hamsters, rabbits, gerbils, guinea pigs, and mice.
  • the host animal is a rodent, still preferably a mouse. It can also be non-human primate (Macacus).
  • the non-human mammal may be in particular an immunocompromised mammal which will generally be incapable of mounting a full immune response against the xenogeneic cells (human hepatocytes).
  • Immunocompromised mammalian hosts suitable for implantation exist or can be created, e.g., by administration of one or more compounds (e.g. , cyclosporine, tacrolimus) or due to a genetic defect which results, e.g., in an inability to undergo germline DNA rearrangement at the loci encoding immunoglobulins and T-cell antigen receptors.
  • Functionality of the human hepatocytes can be monitored by looking at surrogate markers for hepatocyte activity, including physiologic products of human hepatocytes distinguishable from their non-human mammalian, in particular rodents, analogs by immunologic or quantitative criteria, e.g., expression of human serum albumin, or serum bilirubin levels in animals deficient for UGT1A1 activity (also referred as bilirubinemia), etc. These markers can be used to determine the presence of cells without sacrifice of the recipient.
  • the chimeric non-human mammal which comprises functional human hepatocytes may be used in particular as an in vivo model of human hepatitis B infection.
  • Regenerative medicine can be used to potentially cure any disease that results from malfunctioning, damaged or failing tissue by either regenerating the damaged tissues in vivo by direct in vivo implanting of a pharmaceutical composition comprising hepatocyte-like cells (e.g., hepatoblast-like cells) of the disclosure.
  • hepatocyte-like cells e.g., hepatoblast-like cells
  • the disclosure further describes a population of human cells committed in the hepatocyte lineage but not fully differentiated for use in a method of treatment of the human body.
  • the disclosure also relates to a population of human cells committed in the hepatocyte lineage but not fully differentiated for use in the treatment of a liver disease.
  • the disclosure further describes a population of hepatocyte-like cells (e.g., hepatoblast-like cells) of the disclosure for use in a method of treatment of the human body.
  • said population of human hepatoblast-like cells is a population of said cells expressing hepatocyte nuclear factor 4alpha (HNF4 ⁇ ) and do not expressing or substantially not expressing alpha-fetoprotein (AFP) as above-described.
  • HNF4 ⁇ hepatocyte nuclear factor 4alpha
  • AFP alpha-fetoprotein
  • an aspect of the disclosure relates to a population of hepatocyte-like cells (e.g., hepatoblast-like cells) of the disclosure for use in the treatment of a liver disease.
  • said population of human hepatoblast-like cells is a population of said cells expressing hepatocyte nuclear factor 4alpha (HNF4 ⁇ ) and do not expressing or substantially not expressing alpha-fetoprotein (AFP) as above-described.
  • HNF4 ⁇ hepatocyte nuclear factor 4alpha
  • AFP alpha-fetoprotein
  • the disclosure further describes a method for treating a liver disease comprising the step of administering a pharmaceutically effective amount of a population of hepatocyte-like cells (e.g., hepatoblast-like cells) of the disclosure to a patient in need thereof.
  • a pharmaceutically effective amount of a population of hepatocyte-like cells e.g., hepatoblast-like cells
  • treating refers to a method that is aimed at delaying or preventing the onset of a pathology, at reversing, alleviating, inhibiting, slowing down or stopping the progression, aggravation or deterioration of the symptoms of the pathology, at bringing about ameliorations of the symptoms of the pathology, and/or at curing the pathology.
  • the term "pharmaceutically effective amount” refers to any amount of a population of human hepatoblast-like cells according to the disclosure (or a pharmaceutical composition thereof) that is sufficient to achieve the intended purpose.
  • Effective dosages and administration regimens can be readily determined by good medical practice based on the nature of the pathology of the subject, and will depend on a number of factors including, but not limited to, the extent of the symptoms of the pathology and extent of damage or degeneration of the tissue or organ of interest, and characteristics of the subject ( e.g., age, body weight, gender, general health, and the like).
  • populations of human hepatoblast-like cells and pharmaceutical compositions according to the disclosure may be administered through different routes.
  • the dose and the number of administrations can be optimized by those skilled in the art in a known manner.
  • the human hepatoblast-like cells of the disclosure may be useful for autologous regenerative therapy of a patient suffering from a liver disease in need of regenerative therapy due to specific disorders or treatments associated to such disorders, including without limitation, type 1 Crigler-Najjar (CN1) due to the deficit in one identified gene that can be replaced in vitro.
  • CN1 type 1 Crigler-Najjar
  • the disclosure relates to the human hepatoblast-like cells of the disclosure for use as a cell therapy product for implanting into a human patient, as an allogenic graft or, after genetic correction, as an autologous graft (i.e., the cells have the same genotype as the patient's cells).
  • the human hepatoblast-like cells of the disclosure may be useful for bioengineered livers: either by infusing them together with other hepatic-lineage cells into a decellularized liver, by generation of vascularized and functional human liver from human iPSCs by transplantation of liver buds created in vitro ( Takebe et al Nature 2013 499 ), by 3D printing or every other method to generate liver tissue.
  • the human hepatoblast-like cells of the disclosure may be useful for bioartificial livers either by infusing them into extracorporeal devices or embedded them in a biomatrix or hydrogel (such as alginate, silanized hydroxypropyl methylcellulose) before infusion in the body.
  • FIGURES are a diagrammatic representation of FIGURES.
  • EXAMPLE 1 USE OF LN-111 AS A MATRIX FOR DIFFERENTIATING PLURIPOTENT CELLS INTO HEPATOCYTE LINEAGE CELLS AND USE OF HEPATOBLAST-LIKE CELLS-LIKE CELLS THUS OBTAINED IN THERAPY.
  • the BBHX8 hiPSC [46] lines was maintained on Matrigel (BD Biosciences, San Jose, CA, USA)-coated culture wells in mTeSR1 (Stemcell Technologies, Vancouver, BC, Canada) at 37 °C in a 5% CO2 incubator with daily medium changes. Cells were passaged every 5-7 day with Gentle Cell Dissociation Reagent (Stemcell Technologies, Vancouver, BC, Canada).
  • Hepatic Differentiation in vitro Hepatic differentiation of human pluripotent stem cells was performed following a three-step protocol based on previous studies [16, 20, 40] with some modifications.
  • RPMI 1640 supplemented with supplemented with B27 serum-free supplement (Life technologies, Carlsbad, CA, USA) (RPMI/B27), 100 ng/mL Activin A (Miltenyi Biotec, Paris, France), 50 ng/mL WnT3A (R&D systems, Minneapolis, MN, USA), and 10 ⁇ M rock inhibitor (Stemcell Technologies, Vancouver, BC, Canada) for 1 day.
  • Rock inhibitor and Wnt3A were omitted from the medium on the following 2 days and 3 days, respectively. The following 4 days, cells were grown in RPMI 1640/B27 containing 100 ng/mL Activin A and cells were changed daily.
  • FGF fibroblast growth factor
  • BMP bone morphogenetic protein
  • HGF hepatocyte growth factor
  • OSM oncostatin M
  • Immunofluorescence Assay Cultured cells were fixed with 4% paraformaldehyde for 20 min at room temperature, permeabilized with 0.5% Triton X-100 in PBS for 15 min and blocked with 3% BSA in PBS for 15 min. The cells were incubated with primary antibodies for one hour at room temperature.
  • the primary antibodies against human AAT (1:100), CK19 (1:50), and AFP (1:300) were purchased from DAKO (DakoCytomation, Trappes, France); antibodies against human Oct4 (1:100), HNF4 ⁇ (1:100) were purchased from TebuBio (Le Perray-en-Yvelines, France).
  • Flow Cytometry For flow cytometry, differentiated cells were incubated 2 min with Accutase at 37°C. Dissociated cells were fixed with 0.25% paraformaldehyde for 30 min at 4°C, then permeabilized with 0.2% Tween-20 in PBS for 15 min at 37°C. Cells were blocked with 3% BSA/PBS for 30min/4°C in the presence or absence of primary antibodies diluted in 0.5% BSA in PBS. After washing (with PBS) cells were incubated with 3% BSA/PBS following by a 20-minute incubation at 4°C with a donkey anti-mouse Alexa Fluor 488 conjugated antibody. Flow cytometry analysis was performed using a BD LSR II Flow Cytometer (BD Biosciences).
  • Liver function tests Blood was drawn from retro-orbital sinus. Serum total bilirubin and alanine and aspartate aminotransferases were measured at the routine biochemistry department of France University hospital.
  • Histology and Immunohistochemistry Histology and immunohistochemistry were performed by MicroPiCell platform (Nantes). Paraffin-embedded liver sections (5 ⁇ m) were incubated with human Hep Par-1 antibodies (Clone OCH1E5, Dako). Liver sections were counterstained with hematoxylin.
  • RT-qPCR Total mRNA was isolated from cultured cells using the RNeasy minikit (QIAGEN) according to the manufacturer's specifications or TRIzol ® (Lifetechnology, Carlsbad, CA), following the manufacturer's instructions. Isolated mRNA was quantified using a Nanodrop, and a total amount of lOng was used per reaction. Analyses of transcripts were performed with a ViiA7 sequence detection system (Life Technology, Carlsbad, CA, USA) using Power EXPRESS One-Step SYBR ® GreenER TM Kit, (Life Technology, Carlsbad, CA, USA).
  • the mRNA expression level is defined as the fold change in mRNA levels in a given sample relative to levels in undifferentiated cells.
  • ELISA Secretion of human alpha-fetoprotein (AFP) (Calbiotech) and albumin (Bethyl Laboratories) in the culture supernatant were assessed by ELISA according to the manufacturers instructions.
  • AFP alpha-fetoprotein
  • albumin Bethyl Laboratories
  • Hepatocyte transplantation Cells were (1 x 10 7 cells) were detached from the plates using TrypLE, washed, resuspended in 200 ⁇ l physiological serum, and injected with a 26-gauge butterfly needle into the inferior splenic pole of Gunn rats that had been subjected 24 hrs earlier to a two-third partial hepatectomy to create an environment optimal for cell transplantation [48]. Rats were immunosuppressed daily with tacrolimus at 0.2 mg/kg one day before cell transplantation for 3 days and at 0.1 mg/kg thereafter.
  • hiPSC When hiPSC are at 70-90% confluency, cells were harvested and plated onto dishes coated with recombinant LN111. To obtain more reproducible hepatic differentiation process, cells were enzymatically harvested and single cell suspensions were counted and plated in new LN111-coated dishes, instead of using the standard methods based on empirical cell density visualization to evaluate the time and cell ratio splitting to initiate HLCs production.
  • hiPSC were positive for pluripotent markers (Nanog, Sox 2) ( Figure 1B ) and were negative for definitive endoderm (Sox 17, FoxA2) ( Figure 1C ) and hepatic markers (HNF4a, ALB, AFP, Cytochrome P450) ( Figure 1D ).
  • HNF4a hepatic progenitors during the early stages of liver development
  • AFP alpha-fetoprotein
  • AAT alpha-1 antitrypsin
  • CYP3A4 cytochrome P450 3A4
  • hepatoblast-like cells To direct differentiation into hepatoblast-like cells (expression of AFP), cells were cultured in the presence of OSM and HGF for 4 days. After day 20, hiPSC-derived hepatoblasts expressed HNF4a, CK19, AFP and CYP3A7 (a CYP450 enzyme expressed in fetal hepatocytes) and acquired expression of some markers of mature hepatocytes (ALB, AAT, UGT1A1, CYP3A4) and had lost FOXA2 expression, as assessed by RT-qPCR analyses ( Figure 1D ). In accordant to those results, secretion of AFP in cell supernatant was confirmed by ELISA assays. However, we did not detect secretion of albumin, probably because of the low levels of albumin mRNA expression ( Figure IE). Similar results were obtained when hiPSCs were differentiated on Matrigel-coated dishes.
  • Serum levels aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (established markers of hepatocyte injury) in treated rats were 1.59 ⁇ 0.21 ⁇ kat/L and 1.07 ⁇ 0.16 ⁇ kat/L at day 10 post-transplantation, respectively and 2.07 ⁇ 0.85 ⁇ kat/L and 0.95 ⁇ 0.19 ⁇ kat/L at time of sacrifice, respectively.
  • liver engraftment by IDHBs was sustained for a long period (6 months) without signs of tumor formation (carcinoma or teratoma) and liver injury as assessed by histological and blood parameters analyses.
  • IDHBs Like normal primary hepatocyte transplanted in adult livers [51], IDHBs repopulated the liver as single cells, suggesting that they did respond to anti-proliferate stimuli when liver regeneration have terminated and the liver have returned to mitotic quiescence.
  • no teratoma was observed 2 months after direct injection of IDHBs in the testis, confirming the absence of residual undifferentiated hiPSC in the HLC cell preparation.
  • hiPSC-derived endoderm cells have higher engraftment ability than hepatic progenitors-like cells expressing AFP and maturing hepatocytes (expressing albumin) [31]. Conversely, we did not transplant endoderm like-cells (day 5 of differentiation) to reduce the risk of residual undifferentiated hiPSC or not fully differentiated cells in final cell preparations. Loh et al. observed that hiPSC-derived early hepatic progenitors failed to engraft in murine neonate livers.
  • LN-521 recombinant human laminin-521
  • LN-521 can substitute LN-111 as extracellular matrix and allowed better differentiation of hiPSC into definitive endoderm and HLCs as assessed by RT-qPCR analyses of HNF4alpha, AFP, Albumin, AAT expression gene expression ( Figure 3 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP15305265.9A 2015-02-20 2015-02-20 Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells Active EP3059307B2 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
RS20181530A RS58070B2 (sr) 2015-02-20 2015-02-20 Upotreba laminina za diferencijaciju pluripotentnih ćelija u ćelije hepatocitne linije
DK15305265.9T DK3059307T5 (da) 2015-02-20 2015-02-20 Anvendelse af et laminin til differentiering af pluripotente celler i hepatocytcellelinier
HRP20182119TT HRP20182119T4 (hr) 2015-02-20 2015-02-20 Upotreba laminina za diferencijaciju pluripotentnih stanica u stanice hepatocitne linije
LTEP15305265.9T LT3059307T (lt) 2015-02-20 2015-02-20 Laminino panaudojimas pliuripotentinių ląstelių diferenciacijai į hepatocitų linijos ląsteles
HUE15305265A HUE041518T2 (hu) 2015-02-20 2015-02-20 Laminin alkalmazása pluripotens sejtek hepatocita sejtvonalhoz tartozó sejtekké történõ differenciálódásához
SM20190005T SMT201900005T1 (it) 2015-02-20 2015-02-20 Uso di una laminina per la differenziazione di cellule pluripotenti in cellule di lignaggio epatocitario
SI201530533T SI3059307T2 (sl) 2015-02-20 2015-02-20 Uporaba laminina za diferenciacijo pluripotentnih celic v hepatocite
ES15305265T ES2703167T5 (es) 2015-02-20 2015-02-20 Uso de una laminina para diferenciar células pluripotentes en células de linaje hepatocitario
EP15305265.9A EP3059307B2 (en) 2015-02-20 2015-02-20 Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells
PL15305265.9T PL3059307T5 (pl) 2015-02-20 2015-02-20 Zastosowanie lamininy do różnicowania komórek pluripotencjalnych w komórki linii hepatocytów
PT15305265T PT3059307T (pt) 2015-02-20 2015-02-20 Utilização de uma laminina para a diferenciação de células pluripotentes em células de linha hepatocitária
RS20230211A RS64062B1 (sr) 2015-02-20 2016-02-19 Upotreba laminina za diferencijaciju pluripotentnih ćelija u ćelije hepatocitne linije
HUE16705202A HUE061457T2 (hu) 2015-02-20 2016-02-19 Laminin felhasználása pluripotens sejtek hepatocyta vonalú sejtekké történõ differenciálására
CN202010391416.6A CN111548985A (zh) 2015-02-20 2016-02-19 层粘连蛋白用于使多能细胞分化成肝细胞谱系细胞的用途
SI201631673T SI3259345T1 (sl) 2015-02-20 2016-02-19 Uporaba laminina za diferenciranje pluripotentnih celic v celice hepatocitne linije
FIEP16705202.6T FI3259345T3 (fi) 2015-02-20 2016-02-19 Laminiinin käyttö pluripotenttien solujen erilaistamiseen hepatosyyttilinjan soluiksi
JP2017543392A JP6840084B2 (ja) 2015-02-20 2016-02-19 多能性細胞を肝細胞系統の細胞へと分化させるためのラミニンの使用
LTEPPCT/EP2016/053560T LT3259345T (lt) 2015-02-20 2016-02-19 Laminino naudojimas pluripotentinių ląstelių diferenciacijai į hepatocitų linijos ląsteles
DK16705202.6T DK3259345T5 (da) 2015-02-20 2016-02-19 Anvendelse af laminin til differentiering af pluripotente celler i hepatocyt-linie-celler
ES16705202T ES2940191T3 (es) 2015-02-20 2016-02-19 Uso de una laminina para diferenciar células pluripotentes en células de linaje hepatocitario
PCT/EP2016/053560 WO2016131959A1 (en) 2015-02-20 2016-02-19 Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells
PL16705202.6T PL3259345T3 (pl) 2015-02-20 2016-02-19 Zastosowanie lamininy do różnicowania komórek pluripotencjalnych w komórki linii hepatocytów
EP16705202.6A EP3259345B1 (en) 2015-02-20 2016-02-19 Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells
PT167052026T PT3259345T (pt) 2015-02-20 2016-02-19 Utilização de uma laminina para a diferenciação de células pluripotentes em células de linhagem hepatocitária
US15/551,551 US20180030415A1 (en) 2015-02-20 2016-02-19 Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells
CN201680010458.2A CN107532144A (zh) 2015-02-20 2016-02-19 层粘连蛋白用于使多能细胞分化成肝细胞谱系细胞的用途
HRP20230302TT HRP20230302T1 (hr) 2015-02-20 2016-02-19 Uporaba laminina za diferencijaciju pluripotentnih stanica u stanice hepatocitne linije
SM20230078T SMT202300078T1 (it) 2015-02-20 2016-02-19 Uso di una laminina per differenziare cellule pluripotenti in cellule di una stirpe di epatociti
CA2986830A CA2986830C (en) 2015-02-20 2016-02-19 Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells
CY20181101344T CY1121243T1 (el) 2015-02-20 2018-12-14 Χρηση μιας λαμινινης για τη διαφοροποιηση πλειοδυναμων κυτταρων σε κυτταρικες σειρες ηπατοκυτταρων
JP2020167137A JP7132463B2 (ja) 2015-02-20 2020-10-01 多能性細胞を肝細胞系統の細胞へと分化させるためのラミニンの使用
US18/512,545 US20240150721A1 (en) 2015-02-20 2023-11-17 Use of a Laminin for Differentiating Pluripotent Cells into Hepatocyte Lineage Cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15305265.9A EP3059307B2 (en) 2015-02-20 2015-02-20 Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells

Publications (3)

Publication Number Publication Date
EP3059307A1 EP3059307A1 (en) 2016-08-24
EP3059307B1 EP3059307B1 (en) 2018-10-17
EP3059307B2 true EP3059307B2 (en) 2022-05-04

Family

ID=52598699

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15305265.9A Active EP3059307B2 (en) 2015-02-20 2015-02-20 Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells
EP16705202.6A Active EP3259345B1 (en) 2015-02-20 2016-02-19 Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16705202.6A Active EP3259345B1 (en) 2015-02-20 2016-02-19 Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells

Country Status (17)

Country Link
US (2) US20180030415A1 (pl)
EP (2) EP3059307B2 (pl)
JP (2) JP6840084B2 (pl)
CN (2) CN111548985A (pl)
CY (1) CY1121243T1 (pl)
DK (2) DK3059307T5 (pl)
ES (2) ES2703167T5 (pl)
FI (1) FI3259345T3 (pl)
HR (2) HRP20182119T4 (pl)
HU (2) HUE041518T2 (pl)
LT (2) LT3059307T (pl)
PL (2) PL3059307T5 (pl)
PT (2) PT3059307T (pl)
RS (2) RS58070B2 (pl)
SI (2) SI3059307T2 (pl)
SM (2) SMT201900005T1 (pl)
WO (1) WO2016131959A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2917743A1 (en) * 2012-07-12 2014-01-16 Isletone Ab Derivation and self-renewal of isl1+ cells and uses thereof
PL3059307T5 (pl) * 2015-02-20 2023-04-03 Inserm (Institut National De La Santé Et De La Recherche Medicale) Zastosowanie lamininy do różnicowania komórek pluripotencjalnych w komórki linii hepatocytów
EP3368657B1 (en) 2015-10-30 2021-06-30 Biolamina AB Methods for producing hepatocytes
JP7209619B2 (ja) * 2016-07-28 2023-01-20 エフ．ホフマン－ラ ロシュ アーゲー 非ヒト霊長類人工多能性幹細胞由来肝細胞およびその使用
MX2019005476A (es) * 2016-11-16 2019-07-04 Cynata Therapeutics Ltd Ensayo de celulas madre pluripotentes.
CA3051442A1 (en) * 2017-02-14 2018-08-23 Alejandro Soto-Gutierrez Methods of engineering human induced pluripotent stem cells to produce liver tissue
JP6950887B2 (ja) * 2017-04-28 2021-10-13 米満　吉和 体外型の人工肝臓、及び体外型の人工肝臓用又は肝細胞培養用の器具
CA3061599A1 (en) * 2017-05-05 2018-11-08 National University Of Singapore Methods for culturing human keratinocytes
JP2021509812A (ja) 2018-01-05 2021-04-08 プレートレット バイオジェネシス， インコーポレイテッド 巨核球を産生するための組成物および方法
JP7530886B2 (ja) * 2018-05-16 2024-08-08 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 増殖性肝細胞を培養する方法
KR20240033089A (ko) * 2018-06-06 2024-03-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 신경 줄기 세포 조성물 및 신경변성 장애를 치료하는 방법
EP3813853A4 (en) 2018-06-29 2022-04-06 Platelet Biogenesis, Inc. DELIVERY COMPOSITIONS AND METHODS OF USE
US11227435B2 (en) 2018-08-13 2022-01-18 Magic Leap, Inc. Cross reality system
CN110982776B (zh) * 2018-09-30 2023-07-04 中国科学院分子细胞科学卓越创新中心 肝细胞的体外扩增培养方法及应用
EP3969568A4 (en) * 2018-11-09 2022-09-07 Children's Hospital Medical Center IN VITRO CELL CULTURE SYSTEM FOR THE PRODUCTION OF HEPATOCYTE-LIKE CELLS AND USES THEREOF
JP7556502B2 (ja) * 2019-05-09 2024-09-26 フジフィルム セルラー ダイナミクス，インコーポレイテッド ヘパトサイトの作製方法
CA3142666A1 (en) * 2019-06-04 2020-12-10 University Health Network Methods of making and using liver cells
IL296353A (en) * 2020-03-13 2022-11-01 Goliver Therapeutics Hepatic stem-like cells for the treatment and/or the prevention of liver disorders
CN111621467A (zh) * 2020-06-12 2020-09-04 青岛大学 一种诱导人脂肪间充质干细胞分化为肝脏样细胞的方法
CN115851578B (zh) * 2022-12-23 2023-11-21 华南理工大学 一种3d悬浮诱导持续扩增肝祖细胞类器官和/或肝细胞类器官的试剂盒及其应用
KR20260003527A (ko) * 2024-06-28 2026-01-07 재단법인 아산사회복지재단 파수딜과 젤라틴을 이용한 줄기세포 유래 간세포 분화 방법
WO2026071075A1 (ja) * 2024-09-30 2026-04-02 国立研究開発法人国立成育医療研究センター 幹細胞由来肝細胞、当該幹細胞由来肝細胞を含む肝移植用組成物、凍結耐性を有する多能性幹細胞由来肝細胞の製造方法、凍結耐性を有する肝細胞を選別するための分子マーカーの使用、ならびに肝前駆細胞または肝細胞の純化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2985340A1 (en) † 2013-04-08 2016-02-17 National Institutes of Biomedical Innovation, Health and Nutrition Method for culturing hepatoblast-like cells and culture product thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US7332336B2 (en) * 2003-08-19 2008-02-19 Effector Cell Institute, Inc. Methods for inducing differentiation of pluripotent cells
JP2005095138A (ja) * 2003-08-19 2005-04-14 Effector Cell Institute Inc 多分化能を有する細胞の分化誘導方法
WO2006040763A2 (en) 2004-10-12 2006-04-20 Technion Research & Development Foundation Ltd. Isolated primate embryonic cells and methods of generating and using same
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US8741643B2 (en) * 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US8951799B2 (en) * 2007-01-04 2015-02-10 Biolamina Ab Composition and method for enabling proliferation of pluripotent stem cells
JP2010534065A (ja) * 2007-07-20 2010-11-04 セルアーティス アーベー ヒト胚盤胞幹細胞に、胚体内胚葉（ＤＥ‐ｈｅｐ）を介して由来する新規な肝細胞の集団
KR101564044B1 (ko) 2007-10-31 2015-10-28 고쿠리츠 다이가쿠 호진 교토 다이가쿠 핵초기화 방법
WO2009115295A1 (en) 2008-03-17 2009-09-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
WO2010042490A1 (en) 2008-10-06 2010-04-15 Boston Medical Center Corporation A single lentiviral vector system for induced pluripotent (ips) stem cells derivation
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
JP2011010653A (ja) * 2009-06-05 2011-01-20 Kumamoto Univ 細胞の分化誘導方法
CN102666853B (zh) * 2009-10-28 2014-12-03 财团法人日本健康科学振兴财团 由干细胞向肝细胞的分化诱导方法
EP2580319B1 (en) * 2010-06-11 2016-07-20 Takara Bio Europe AB 3-dimensional scaffolds for improved differentiation of pluripotent stem cells to hepatocytes
BR112013017629A2 (pt) 2010-12-17 2017-04-18 Biolamina Ab laminina-521 recombinante
CA2849244C (en) * 2011-09-22 2023-10-10 Karl Tryggvason Cell culture substrate comprising a laminin and a cadherin
US20130330825A1 (en) * 2012-06-07 2013-12-12 City Of Hope Attachment substrates for directed differentiation of human embryonic stem cells in culture
CN104884468B (zh) * 2012-12-28 2018-08-31 国立大学法人大阪大学 附加有胶原结合性分子的改造层粘连蛋白及其利用
KR20210018540A (ko) * 2013-02-18 2021-02-17 유니버시티 헬스 네트워크 다능성 줄기세포로부터 간세포 및 담관세포의 생성 방법
PL3059307T5 (pl) * 2015-02-20 2023-04-03 Inserm (Institut National De La Santé Et De La Recherche Medicale) Zastosowanie lamininy do różnicowania komórek pluripotencjalnych w komórki linii hepatocytów

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2985340A1 (en) † 2013-04-08 2016-02-17 National Institutes of Biomedical Innovation, Health and Nutrition Method for culturing hepatoblast-like cells and culture product thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
INAMURA ET AL, MOLECULAR THERAPY, vol. 19, no. 2, 2011, pages 400 - 407 †
SHIRAKI ET AL, PLOS ONE, vol. 6, no. 8, 2011, pages e2428 †
TAKAYAMA ET AL, STEM CELL REPORTS, vol. 1, no. 4, 2013, pages 322 - 335 †
UNGER ET AL, HUMAN MOLECULAR GENETICS, vol. 17, no. 1, 2008, pages R48 - R53 †

Also Published As

Publication number Publication date
DK3059307T3 (en) 2019-01-14
SI3259345T1 (sl) 2023-08-31
ES2703167T3 (es) 2019-03-07
JP6840084B2 (ja) 2021-03-17
HRP20182119T4 (hr) 2022-09-02
EP3059307A1 (en) 2016-08-24
SI3059307T1 (sl) 2019-03-29
CN111548985A (zh) 2020-08-18
HRP20182119T1 (hr) 2019-03-08
DK3059307T4 (da) 2022-08-01
SI3059307T2 (sl) 2022-08-31
CN107532144A (zh) 2018-01-02
HUE041518T2 (hu) 2019-05-28
LT3059307T (lt) 2019-01-10
US20180030415A1 (en) 2018-02-01
HRP20230302T1 (hr) 2023-05-12
EP3259345A1 (en) 2017-12-27
CY1121243T1 (el) 2020-05-29
SMT202300078T1 (it) 2023-05-12
DK3059307T5 (da) 2022-08-29
RS58070B1 (sr) 2019-02-28
ES2703167T5 (es) 2022-09-30
PL3059307T3 (pl) 2019-05-31
US20240150721A1 (en) 2024-05-09
LT3259345T (lt) 2023-03-27
DK3259345T5 (da) 2024-10-14
JP2018508207A (ja) 2018-03-29
FI3259345T3 (fi) 2023-04-03
HUE061457T2 (hu) 2023-06-28
JP2021006054A (ja) 2021-01-21
PL3259345T3 (pl) 2023-05-02
SMT201900005T1 (it) 2019-05-10
PT3059307T (pt) 2019-01-23
ES2940191T3 (es) 2023-05-04
RS58070B2 (sr) 2022-10-31
RS64062B1 (sr) 2023-04-28
DK3259345T3 (da) 2023-03-27
JP7132463B2 (ja) 2022-09-07
CA2986830A1 (en) 2016-08-25
PT3259345T (pt) 2023-03-15
EP3259345B1 (en) 2023-02-08
WO2016131959A1 (en) 2016-08-25
EP3059307B1 (en) 2018-10-17
PL3059307T5 (pl) 2023-04-03

Similar Documents

Publication Publication Date Title
US20240150721A1 (en) Use of a Laminin for Differentiating Pluripotent Cells into Hepatocyte Lineage Cells
JP2018508207A5 (pl)
CA3064220C (en) Liver organoid, its uses, and the culture method for obtaining it
Dianat et al. Human pluripotent stem cells for modelling human liver diseases and cell therapy
US9005964B2 (en) Endodermal progenitor cells
US20130031645A1 (en) Method for hepatic differentiation of definitive endoderm cells
CN103981147A (zh) 一种新的制备肝实质细胞的方法
US20140023624A1 (en) Decellularized liver transplantation composition and methods
JPWO2011016485A1 (ja) ｉＰＳ細胞から肝実質細胞への分化誘導方法
CA2986830C (en) Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells
HK40026459A (en) Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells
Tafaleng Modeling the personalized variations in liver disease due to α1-antitrypsin deficiency using induced pluripotent stem cell-derived hepatocyte-like cells
HK1188253A (en) Liver organoid, uses thereof and culture method for obtaining them
HK1188253B (en) Liver organoid, uses thereof and culture method for obtaining them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170224

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170523

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015018234

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12N0005071000

Ipc: A01K0067027000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/071 20100101ALI20180322BHEP

Ipc: A01K 67/027 20060101AFI20180322BHEP

INTG Intention to grant announced

Effective date: 20180413

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FOURRIER, ANGELIQUE

Inventor name: NGUYEN, TUAN HUY

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

111L Licence recorded

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Free format text: EXCLUSIVE LICENSE

Name of requester: GOLIVER THERAPEUTICS, FR

Effective date: 20180626

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Free format text: EXCLUSIVE LICENSE

Name of requester: QUEST VALORISATION, FR

Effective date: 20180626

111L Licence recorded

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Free format text: EXCLUSIVE LICENSE

Name of requester: GOLIVER THERAPEUTICS, FR

Effective date: 20180626

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Free format text: EXCLUSIVE LICENSE

Name of requester: QUEST VALORISATION, FR

Effective date: 20180626

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

R11L Licence recorded (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Free format text: EXCLUSIVE LICENSE

Name of requester: GOLIVER THERAPEUTICS, FR

Effective date: 20180626

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Free format text: EXCLUSIVE LICENSE

Name of requester: OUEST VALORISATION, FR

Effective date: 20180626

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1052871

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181115

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015018234

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20182119

Country of ref document: HR

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190106

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3059307

Country of ref document: PT

Date of ref document: 20190123

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190114

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: STOLMAR AND PARTNER INTELLECTUAL PROPERTY S.A., CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20181017

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2703167

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20190307

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20182119

Country of ref document: HR

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182119

Country of ref document: HR

Payment date: 20190219

Year of fee payment: 5

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E016691

Country of ref document: EE

Effective date: 20181217

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180403775

Country of ref document: GR

Effective date: 20190404

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E041518

Country of ref document: HU

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 29811

Country of ref document: SK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602015018234

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: CYTOCHROMA LTD

Effective date: 20190717

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182119

Country of ref document: HR

Payment date: 20200204

Year of fee payment: 6

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

REG Reference to a national code

Ref country code: HU

Ref legal event code: HC9C

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA, FR

Ref country code: HU

Ref legal event code: HC9C

Owner name: UNIVERSITE DE NANTES, FR

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182119

Country of ref document: HR

Payment date: 20210212

Year of fee payment: 7

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1052871

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181017

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182119

Country of ref document: HR

Payment date: 20220216

Year of fee payment: 8

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20220504

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: NANTES UNIVERSITE

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602015018234

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20220726

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: NANTES UNIVERSITE; FR

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: UNIVERSITE DE NANTES

Effective date: 20220718

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: NO

Ref legal event code: TB2

REG Reference to a national code

Ref country code: EE

Ref legal event code: GB1A

Ref document number: E016691

Country of ref document: EE

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

REG Reference to a national code

Ref country code: DK

Ref legal event code: T5

Effective date: 20220826

REG Reference to a national code

Ref country code: HR

Ref legal event code: T4IZ

Ref document number: P20182119

Country of ref document: HR

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20220818 AND 20220824

REG Reference to a national code

Ref country code: EE

Ref legal event code: LD4A

Ref document number: E016691

Country of ref document: EE

REG Reference to a national code

Ref country code: SK

Ref legal event code: T5

Ref document number: E 29811

Country of ref document: SK

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2703167

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20220930

REG Reference to a national code

Ref country code: HR

Ref legal event code: PPPP

Ref document number: P20182119

Country of ref document: HR

Owner name: NANTES UNIVERSITE, FR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20220401557

Country of ref document: GR

Effective date: 20221010

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: INSERM(INSTITUT NATIONAL DE LA SANTE ET DE LA ; FR

Effective date: 20221005

REG Reference to a national code

Ref country code: HU

Ref legal event code: HC9C

Owner name: NANTES UNIVERSITE, FR

Free format text: FORMER OWNER(S): UNIVERSITE DE NANTES, FR

Ref country code: HU

Ref legal event code: HC9C

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), FR

Free format text: FORMER OWNER(S): UNIVERSITE DE NANTES, FR

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): DR. KOCSOMBA NELLI UEGYVEDI IRODA, HU

Representative=s name: DR. KOCSOMBA NELLI UEGYVEDI IRODA, HU

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: NANTES UNIVERSITE; FR

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: UNIVERSITE DE NANTES

Effective date: 20220926

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182119

Country of ref document: HR

Payment date: 20230214

Year of fee payment: 9

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 1052871

Country of ref document: AT

Kind code of ref document: T

Owner name: NANTES UNIVERSITE, FR

Effective date: 20230117

Ref country code: AT

Ref legal event code: PC

Ref document number: 1052871

Country of ref document: AT

Kind code of ref document: T

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA, FR

Effective date: 20230117

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015018234

Country of ref document: DE

Owner name: NANTES UNIVERSITE, FR

Free format text: FORMER OWNERS: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), PARIS, FR; UNIVERSITE DE NANTES, NANTES, FR

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015018234

Country of ref document: DE

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA, FR

Free format text: FORMER OWNERS: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), PARIS, FR; UNIVERSITE DE NANTES, NANTES, FR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182119

Country of ref document: HR

Payment date: 20240209

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182119

Country of ref document: HR

Payment date: 20250207

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250218

Year of fee payment: 11

Ref country code: LU

Payment date: 20250218

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20250220

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20250227

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20250206

Year of fee payment: 11

Ref country code: HR

Payment date: 20250207

Year of fee payment: 11

Ref country code: IS

Payment date: 20250211

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20250224

Year of fee payment: 11

Ref country code: FI

Payment date: 20250220

Year of fee payment: 11

Ref country code: RO

Payment date: 20250211

Year of fee payment: 11

Ref country code: SM

Payment date: 20250124

Year of fee payment: 11

Ref country code: LT

Payment date: 20250123

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20250221

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250220

Year of fee payment: 11

Ref country code: SE

Payment date: 20250218

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20250221

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20250206

Year of fee payment: 11

Ref country code: BE

Payment date: 20250218

Year of fee payment: 11

Ref country code: GR

Payment date: 20250220

Year of fee payment: 11

Ref country code: LV

Payment date: 20250218

Year of fee payment: 11

Ref country code: EE

Payment date: 20250214

Year of fee payment: 11

Ref country code: AT

Payment date: 20250219

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250214

Year of fee payment: 11

Ref country code: CZ

Payment date: 20250212

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20250224

Year of fee payment: 11

Ref country code: SK

Payment date: 20250211

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RS

Payment date: 20250207

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20250210

Year of fee payment: 11

Ref country code: MT

Payment date: 20250127

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20250215

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250331

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250220

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20250123

Year of fee payment: 11

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1052871

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220504

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20250122

Year of fee payment: 11

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260301

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20260227

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20260227

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20260227

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20260301

Year of fee payment: 12